Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record.

Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?

Hennes, Elke M., Oo, Ye H., Schramm, Christoph, Denzer, Ulrike, Buggisch, Peter, Wiegard, Christiane, Kanzler, Stephan, Schuchmann, Marcus, Boecher, Wulf, Galle, Peter R., Adams, David H., Lohse, Ansgar W. · 2008 · The American Journal of Gastroenterology

Abstract

INTRODUCTION: In patients with autoimmune hepatitis, efficient immunosuppressive therapy is essential to avoid progression to cirrhosis. There is no established second line therapy for patients failing standard therapy with steroids and azathioprine. The aim of this study was to examine the possible role of mycophenolate mofetil (MMF) as second line treatment of autoimmune hepatitis (AIH). PATIENTS AND METHODS: We were able to identify 37 patients (29 women, 8 men) with AIH proven according to International AIH Group criteria who failed standard therapy. One patient on MMF was excluded due to non-compliance. A total of 28 of 36 patients had experienced side effects necessitating stop of treatment. One patient stopped azathioprine due to pregnancy. A total of nine patients did not respond sufficiently to azathioprine. A total of four patients with a treatment duration of 3 months or less because of severe side effects were considered as intolerant to MMF. Remission was defined as aspartate transaminase (ASP) < twice upper normal limit (UNL). RESULTS: Of 36 patients on MMF included in the analysis, 14 patients (39%) experienced remission. A total of 22 patients (61%) did not respond sufficiently to MMF. The response rate to MMF was dependent on the cause of treatment cessation of azathioprine. Of eight patients with prior nonresponse to azathioprine, six (75%) did not respond to MMF and only two (25%) reached biochemical remission. Of 28 patients with azathioprine intolerance in 16 (57%) patients, the response to MMF was insufficient and in 12 patients (43%) remission was reached. The difference did not reach statistical significance due to the relatively small numbers included. CONCLUSION: In the light of its good tolerability, MMF seems to be an alternative for patients who could not tolerate azathioprine previously. However, our data suggest that a majority of patients fail MMF particularly if they are switched because of an insufficient response to azathioprine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1572-0241.2008.02180.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
Hennes, E. M., Oo, Y. H., Schramm, C., Denzer, U., Buggisch, P., Wiegard, C., Kanzler, S., Schuchmann, M., Boecher, W., Galle, P. R., Adams, D. H., & Lohse, A. W.
Venue
The American Journal of Gastroenterology
Published
2008-12
Volume
103
Issue
12
Pages
3063-3070
ISSN
  • 0002-9270 (ISSN-L)
  • 1572-0241
OpenAlex
W1973339766
Cited by
188
References
0
FWCI
9.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis? https://app.cochat.ai/papers/10.1111/j.1572-0241.2008.02180.x
The paper
Hennes, E. M., Oo, Y. H., Schramm, C., Denzer, U., Buggisch, P., Wiegard, C., Kanzler, S., Schuchmann, M., Boecher, W., Galle, P. R., Adams, D. H., & Lohse, A. W. (2008). Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis? The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2008.02180.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.